We are live on ! Find out more
CIA

Capital Impact Advisors Portfolio holdings

AUM $247M
1-Year Est. Return 31.15%
This Fund
S&P 500
This Quarter Est. Return
+3.65%
1 Year Est. Return
+31.15%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$100M
AUM Growth
-$7.81M
Cap. Flow
-$11.3M
Cap. Flow %
-11.27%
Top 10 Hldgs %
11.69%
Holding
238
New
12
Increased
100
Reduced
117
Closed
1

Sector Composition

Rank Sector Weight
1 Technology 29.49%
2 Healthcare 26.32%
3 Consumer Discretionary 12.34%
4 Industrials 8.94%
5 Financials 6.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UPST icon
226
Upstart Holdings
UPST
$2.82B
$76K 0.08%
3,896
-2,902
-43% -$78K
BSY icon
227
Bentley Systems
BSY
$10.9B
$68K 0.07%
2,226
-740
-25% -$27.1K
NIU
228
Niu Technologies
NIU
$202M
$65K 0.06%
17,566
+6,358
+57% +$38.9K
CELL
229
DELISTED
PhenomeX Inc. Common Stock
CELL
$65K 0.06%
+21,805
New +$92.7K
MTLS
230
Materialise
MTLS
$377M
$62K 0.06%
+6,127
New +$78K
DKNG icon
231
DraftKings
DKNG
$11.7B
$58K 0.06%
+3,878
New +$61.6K
CERS icon
232
Cerus
CERS
$433M
$49K 0.05%
+12,834
New +$61.4K
TSP
233
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
$47K 0.05%
+18,630
New +$156K
LEGH icon
234
Legacy Housing
LEGH
$625M
$41K 0.04%
2,439
+800
+49% +$12.7K
CVX icon
235
Chevron
CVX
$385B
$31K 0.03%
217
-72
-25% -$11K
VLO icon
236
Valero Energy
VLO
$88.5B
$27K 0.03%
250
-83
-25% -$9.13K
CLR
237
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$23K 0.02%
338
-112
-25% -$7.56K
GBT
238
DELISTED
Global Blood Therapeutics, Inc.
GBT
-24,167
Closed -$772K

Similar funds

Capital Impact Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Capital Impact Advisors held 238 positions worth $100M, down 7.2% from $108M the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Capital Impact Advisors withdrew a net $11.3M in Q3 2022, closing 1 position and reducing 117 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $772K position sold in full.

By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Capital Impact Advisors opened a new position in Ginkgo Bioworks worth $118K.

  • Capital Impact Advisors's largest Q3 2022 buy was Ginkgo Bioworks: 1,374 shares worth $118K.
  • Capital Impact Advisors added most to Arhaus in Q3 2022, an estimated $228K increase.
  • Capital Impact Advisors's biggest Q3 2022 reduction was e.l.f. Beauty, cutting an estimated $919K.
  • Capital Impact Advisors fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $772K.
  • Capital Impact Advisors's ten largest holdings make up 12% of its $100M portfolio in Q3 2022.
  • Capital Impact Advisors opened 12 new positions and closed 1 in Q3 2022.
  • Capital Impact Advisors's portfolio value fell 7.2% quarter-over-quarter to $100M.

Based on Capital Impact Advisors's 13F filing for Q3 2022, filed 22 Nov 2022.